

Michael H McGuire

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8473726/michael-h-mcguire-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

586
citations

10
h-index

16
g-index

16
ext. papers

760
ext. citations

10.8
avg, IF

2.52
L-index

#	Paper	IF	Citations
15	Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype. <i>Cell Reports</i> , 2021 , 34, 108726	10.6	8
14	Gene Body Methylation of the Lymphocyte-Specific Gene Results in Its Overexpression and Regulates Cancer mTOR Signaling. <i>Molecular Cancer Research</i> , 2021 , 19, 1917-1928	6.6	2
13	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. <i>Cell Reports</i> , 2021 , 36, 109549	10.6	2
12	Pan-cancer genomic analysis links 3dJTR DNA methylation with increased gene expression in T cells. <i>EBioMedicine</i> , 2019 , 43, 127-137	8.8	18
11	/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 162-172	6.1	11
10	FABP4 as a key determinant of metastatic potential of ovarian cancer. <i>Nature Communications</i> , 2018 , 9, 2923	17.4	82
9	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 464-473	6.1	3
8	Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	7
7	PRKCI promotes immune suppression in ovarian cancer. <i>Genes and Development</i> , 2017 , 31, 1109-1121	12.6	43
6	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016 , 7, 11169	17.4	83
5	Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. <i>JCI Insight</i> , 2016 , 1, e87754	9.9	10
4	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1344-52	6.1	30
3	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. <i>Cell Reports</i> , 2015 , 13, 2395-2402	10.6	75
2	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. <i>Nature Communications</i> , 2014 , 5, 5202	17.4	130
1	2aOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014 , 5, 3459	17.4	81